Kornimate/medical-research-clean huggingface dataset:
cross-linking accéléré iontophorèse confocal kératocone

Conditions: Keratoconus

Summary: a monocentric, parallel-arm, prospective, randomized therapeutic trial that compares the efficacy of two curative keratoconus treatment techniques by cross-linking collagen (accelerated conventional technique or iontophoresis). the primary endpoint will be the depth of the demarcation line measured by confocal microscopy and oct at 1 month. this line represents the limit depth between treated and untreated stroma.

a two-arm, parallel, open-label, prospective, randomized therapeutic trial comparing two management strategies. the goal is to describe and compare, thanks to in vivo confocal microscopy and optical coherence tomography (oct), the structural modifications observed postoperatively on evolutive keratoconus treated by cross-linking of collagen in accelerated procedure and iontophoresis. the study will be monocentric and will take place in the ophthalmology department of clermont-ferrand university hospital. patients will be recruited through consultation dedicated to keratoconus (the ophthalmology department of clermont-ferrand is one of the 9 french centers of expertise for this pathology). inclusion will be offered to all patients over 18 years old who meet the scalability criteria and who will benefit from a cross-linking procedure. blind randomization will be performed between iontophoresis and accelerated procedure. the dates of the visits will be fixed, with a preoperative evaluation, and a follow-up follow-up on 6 months with controls at 1 month, 3 months and 6 months. confocal microscopy imaging and oct will be performed during the preoperative visit and during visits at 1 month, 3 months and 6 months.

Eligibility criteria:
inclusion criteria: * pachymetry greater than 400μm topographic criteria for keratoconus evolution: variation over a period of 6 months of the following parameters: an increase equal to or greater than 1d of maximum keratometry (kmax) and / or an increase in mean keratometry (kmean) greater than or equal to 0.75d and / or an increase in the difference between the most arched and the least arched meridian (kmax-kmin) greater than or equal to 0.75d and / or a decrease in corneal central thickness greater than or equal to 2% exclusion criteria: ectasies post lasik pregnant women breastfeeding major corneal opacities absence of consent to participate in the study no affiliation to social security or state medical aid (ame) or universal medical coverage (cmu)

Keywords: keratoconus cross-linking confocal microscopy postoperative morphological iotonphoresis
the effect of instant message intervention for psychological well-being among stroke survivors

Conditions: Stroke; Depressive Symptoms; Mobile Phone Use

Summary: the proposed pilot trial aims to evaluate the feasibility of icbt based emi, which is a real-time, real-world, personalised and cost-effective approach, for stroke survivors' psychological well-being.


Eligibility criteria:
inclusion criteria: * diagnosis of stroke (icd-10 codes: i60-i69) * aged ≥18 * able to read and communicate in chinese (cantonese or putonghua) * able to use text messaging function on mobile phones * moca 5-minute protocol (cognitive screen) ≥14 (equivalence to mmse ≥ 21) * discharged home from hospital within preceding 6 months * phq-9 (depressive symptom) score range from 5 to 19 (cf. mild: 5-9, moderate: 10-14, moderately severe: 15-19 and severe: 20-27) exclusion criteria: * currently receiving active stroke care in acute or post-acute inpatient settings * has diagnosis of psychiatric disease or is currently taking psychotropic drug * phq-9 ≥ 20 (i.e., severe depressive symptom) * currently participating in any type of psychological intervention (e.g., cbt)
effects of bisphosphonates and nutritional supplementation after a hip fracture

Conditions: Hip Fracture

Summary: the study hypothesis is that nutritional supplementation together with bisphosphonates have a better preserving effect on bone mineral density (bmd) after hip fracture than bisphosphonates alone and that nutritional supplementation given postoperatively for 6 months preserve lean body mass in elderly hip fracture patients.

inclusion criteria: men and women, ≥ 60 years of age with a recent fracture of the femoral neck or trochanter, admitted to any of the four university hospitals in stockholm, sweden. patients are randomized into three groups by sealed enveloped technique in blocks by 12, thus assuring that each center had an equal distribution of patients in the three treatment groups. patients randomly assigned and followed for 12 months. each center with a doctor in charge and a trial nurse. the trial nurse in collaboration with the doctor are responsible of the randomization procedure and that blood samples are taken in the morning of the first weekday after inclusion at the ward and further that the dual-energy x-ray (dxa) and all estimates are done during hospital stay.the pharmacological treatment and nutritional supplementation starts as soon as the patients are circulatory stable, able to take food by mouth and are able to sit in an upright position one hour after taking the tablets.patients are examined at baseline with a follow up at 6 and 12 months.

Eligibility criteria:
inclusion criteria: * age ≥ 60 years * recent fracture of the femoral neck or trochanter * without severe cognitive impairment * ambulant before fracture * bmi ≤ 28 exclusion criteria: * abnormal parameters regarding liver i.e. s-alanine aminotransferase (s-alat) and s-aspartate aminotransferase (s-asat) ≥ twice as normal * abnormal parameters regarding kidney i.e. s-creatinine \> 130 µg/l * primary hyperparathyroidism, osteogenesis imperfecta, paget´s disease * myeloma * lactose intolerance * dysphagia * esophagitis * gastric ulcer * malignancy * diabetes with nephropathy or retinopathy * active iritis or uveitis

Keywords: hip fracture nutritional supplement bisphosphonates bone mineral density body composition
the evaluation of safety, tolerability and pharmacokinetics/pharmacodynamics of jpi-289 in healthy male volunteers

Conditions: Stroke

Summary: double blind, randomized, placebo control, multiple dose, dose escalation study

a phase i clinical study, randomized, double-blind, placebo-controlled, multiple doses, dose escalation study of the safety, tolerability and pharmacokinetics/pharmacodynamics of jpi-289 in healthy male volunteers.

Eligibility criteria:
inclusion criteria: * 19\~55 years healthy male * bmi measurement 20kg/m²\~27kg/m² * 90 ≤ sbp\<140(mmhg) 60 ≤ dbp\<100(mmhg) 45 ≤ pulse rate\<100(bpm) * signed the informed consent form to participate voluntarily and to comply with the trial requirements * for a follow-up visit and during the study period, blood samples and availability exclusion criteria: * history of clinically significant hepatic, gastrointestinal, pulmonary, musculoskeletal, endocrine, psychiatric, hematooncologic, cardiovascular (specially asthma, obstructive pulmonary disease, peptic ulcer) * history of skin disease of graft affecting absorption of the drug * history of drug abuse * positive urine drug screening * administrated investigational product in a previous clinical trial within 60 days of the screening test * donated blood within 60 days prior to screening test
the effect of square dance on rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to observe the effect of square dance on rheumatoid arthritis.


Eligibility criteria:
inclusion criteria: * had wrist and/or mcp involvement * aged 18 years diagnosed by rheumatology consultants with ra exclusion criteria: * severe psychological difficulties * currently receiving mental health care * any medical condition that might prevent them from safely exercising (e.g. history of more severe heart, lung or cerebrovascular disease) * previously attended an education programme * had a modified health assessment questionnaire score above 2 (0-3)
efficacy and safety of parecoxib on morphine patient-controlled epidural analgesia (pcea) after gynecologic surgery

Conditions: Benign Female Reproductive System Neoplasm

Summary: the purpose of this study is to determine the effects of parecoxib in combination with epidural morphine in providing analgesia for patients undergoing gynecological surgery.

researches have showed that the use of epidural and spinal block resulted in significant reduction in morbidity and mortality after surgery. moreover, appropriate pain management results in better outcomes. opioids therapy is recommended as the first choice medication for the management of postoperative pain but is associated with a number of undesirable adverse effects. a multimodal therapy for providing postoperative analgesia has advantages over the use of opioids alone. the use of nsaids and opioids together often improves analgesia and reduces the need for opioids in the postoperative period. often, the combination of cox-2 inhibitors with epidural analgesia is preferred. with epidural analgesia, addition of cox-2 inhibitors may improve the analgesia and decrease the undesirable side effects.

Eligibility criteria:
inclusion criteria: * women scheduled for elective gynecological surgery under combined spinal-epidural anesthesia exclusion criteria: * contraindications for cse placement * known allergy, sensitivity, or contraindication to opioid and nonopioid analgesic drugs * history of bleeding disorders, peptic ulceration, or anticoagulant use within the past month * current pregnancy or breastfeeding * history of known or suspected drug abuse * unable to understand the use of pain assessment scales and the pca device * patient with asthma or bronchospasm, requiring treatment with glucocorticoids * poorly controlled hypertension or diabetes, a chronic or acute renal or hepatic disorder, or inflammatory bowel disease * patients had taken antidepressants, narcotic analgesics, antihistamines, anxiolytics, hypnotics, sedatives, nsaids, or corticosteroids up to 24 h before receipt of the study medication

Keywords: cyclooxygenase inhibitors morphine analgesia patient-controlled gynecologic surgical procedures
orthovisc shoulder osteoarthritis study

Conditions: Glenohumeral Osteoarthritis

Summary: a comparison of orthovisc to corticosteroid injections in the shoulder for pain due to osteoarthritis.

this multicenter, prospective double-blinded, randomized trial will study two treatment groups. subjects will be randomized to receive either orthovisc or corticosteroids/anesthetic injection into the shoulder in a 2:1 schema. the trial will assess safety and efficacy of pain relief in the osteoarthritic shoulder.

Eligibility criteria:
inclusion criteria: * a candidate for unilateral treatment of osteoarthritis of the shoulder * have failed conservative treatment exclusion criteria: * presence of full thickness rotator cuff tear and/or significantly compromised rotator cuff function * no active instability or acute dislocation episodes within the previous 12 months * known allergy to hyaluronate preparations * pregnant or breast feeding * is receiving prescription pain medication for conditions unrelated to the index shoulder condition

Keywords: orthovisc osteoarthritis shoulder randomized
lower extremity elevation to minimize hemodynamic instability during induction of general anesthesia

Conditions: Post Induction Hypotension

Summary: the purpose of this study is to determine if lower extremity elevation (lee) will reduce the incidence of postinduction hypotension, to compare the utilization of vasoactive medications after induction in patients with lee and patients without lee and to determine if lee will increase measured cardiac output


Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa)3 or lower * patients requiring general anesthesia exclusion criteria: * allergic reaction to drugs commonly used for general anesthesia including fentanyl, midazolam, propofol, ephedrine and phenylephrine * pregnant women * requiring rapid sequence induction * prisoners * patient refusal * emergency surgery

Keywords: hypotension
effects of music based intervention (mbi) on pain response and neurodevelopment in preterm infants

Conditions: Preterm Birth; Pain

Summary: pilot prospective randomized, double blinded, controlled study to test effect of music based intervention (mbi) on pain response and neurodevelopment in preterm infants.

aim 1: premature infant pain profiles (pipp) include physiologic, behavioral, and contextual measures which identifies differences in pain responses between music-based intervention (mbi) and controls while still in the neonatal intensive care unit (nicu). central eeg amplitude changes have been time-locked with painful procedures in term infants. we will explore if pipp scores and central eeg amplitude changes are attenuated with mbi in comparison to controls. hypothesis 1: mbi will show improved pain responses, with lower pipp scores and attenuated central eeg amplitude changes during painful procedures, in comparison to the control cohort. aim 2: eeg is a surrogate marker for real time brain function during sleep-wake cycles. because preterm brain networks develop during sleep, sleep duration is a strong indicator of brain maturation. serial biweekly eegs of preterm infants can quantify sleep duration trends and track mbi's influence on sleep. to enhance objectivity, innovative eeg machine-learning tools will be applied to the analyses. hypothesis 2: mbi will enhance preterm eeg brain maturation in comparison to controls. due to the natural limitations of evaluating immature neonatal nervous systems, erps have been utilized to study early neurodevelopment. erps quantify electrical brain potentials changes time-locked with a stimulus. auditory erps performed at 1 month corrected age evaluates attention and discrimination between familiar and novel stimuli - early neurodevelopmental signs of recognition memory function and perceptual learning. hypothesis 3: erps at 1 month corrected age will show that mbi has a greater impact on early neurodevelopment when compared to controls.

Eligibility criteria:
inclusion criteria: * preterm infant born at 30 weeks (+/- 2 weeks) * medically stable exclusion criteria: * treatment for major organ system disease * significant neurological disorder including, but not limited to, abnormal neurological examination, neonatal abstinence syndrome, intraventricular hemorrhage, seizures, meningitis, or congenital brain malformations * scalp lesions affecting eeg placement

Keywords: music based intervention preterm infant pain profile
increasing uptake of bowel screening

Conditions: Colorectal Cancer

Summary: bowel cancer is the second biggest cancer killer in the uk, accounting for over 16,000 deaths per year. screening can reduce deaths from bowel cancer if the people invited participate. the challenge is that high uptake of bowel screening is hard to achieve, and remains persistently below 65%. the faecal immunochemical test (fit) is the most widely used bowel screening test worldwide. in the uk, fit kits are mailed to people's homes without guidance on when the kit should be returned and only brief instruction on how to use it. some people have said that even though they intend to complete and return the kit, they often forget or put off doing it. two approaches are proposed to addressing this issue: i) providing a suggested deadline for fit return, because it is known from breast and cervical cancer screening that giving people an appointment time increases uptake compared to an open invitation, and ii) planning sheets, that have been found to help people act on their intentions in other health contexts. this trial aims to evaluate the impact of providing a suggested deadline and a planning sheet on the return of fit bowel screening kits. the trial is integrated within the scottish bowel screening programme. the investigators will randomly allocate 40,000 consecutive people that are due to be sent a fit kit to one of eight groups: (i) control group (no deadline, no planning sheet), (ii) intervention group (1-week deadline, no planning sheet), (iii) intervention group (2-week deadline, no planning sheet), (iv) intervention group (4-week deadline, no planning sheet), (v) intervention group (no deadline, with planning sheet), (vi) intervention group (1-week deadline, with planning sheet), (vii) intervention group (2-week deadline, with planning sheet), (viii) intervention group (4-week deadline, with planning sheet). it will then be examined if having a suggested deadline and a planning sheet affects how many people send back their completed fit kit. it will also be examined if the deadline length makes a difference and whether having both a deadline and a planning sheet affects the number of people returning their kit. finally, the cognitive and behavioural mechanisms underlying any intervention effects will be assessed and the acceptability of the interventions explored, using questionnaires and in-depth interviews.


Eligibility criteria:
inclusion criteria: * 50-74 years * registered with a community health index number in scotland * more than 2 years since last bowel screening invitation exclusion criteria: * has self-excluded from scottish bowel screening programme * not sent a screening kit by the scottish bowel screening programme

Keywords: early detection of cancer
prospective multicenter clinical study of neoadjuvant imatinib mesylate for gastrointestinal stromal tumors

Conditions: Progression-free Survival; Gastrointestinal Stromal Tumor; Neoadjuvant

Summary: the r0 resection rate of gastrointestinal stromal tumor (gist) with high recurrence risk was relatively low, and the relapse-free survival rate was relatively low, which needed to be further improved. a few retrospective analyses and a small sample of prospective studies have found that neoadjuvant therapy with imatinib mesylate can improve r0 resection rates. whether neoadjuvant therapy prolongs long-term survival remains unclear. the primary objective of this study was to evaluate 5-year progression-free survival (pfs) for gist patients with high recurrence risk after neoadjuvant treatment with imatinib mesylate.


Eligibility criteria:
inclusion criteria: * preoperative histologically confirmed primary gastrointestinal stromal tumor * tumor must stain positive for c-kit (cd117) and/or discovered on gist-1 (dog-1) by immunohistochemistry * gene mutation test report including c-kit exons 9,11,13 and 17 and platelet-derived growth factor receptor alpha (pdgfra) exons 12 and 18 * high risk gist (as modified national institutes of health (nih) 2008): stomach (maximum tumor diameter\> 10.0cm), nonstomach (maximum tumor diameter\> 5.0cm) * gender is not limited. age: ≥ 18 years and ≤ 80 years old * performance status: eastern cooperative oncology group (ecog) 0-1 * patient had informed consent and signed a written consent form exclusion criteria: * asp842val (d842v) mutation in exon 18 of pdgfra gene, or wild type (c-kit exon 9,11,13,17, and pdgfra exon 12,18), or c-kit exon 9 mutation * treated with tyrosine kinase inhibitors including imatinib * aspartate aminotransferase (ast) and/or alanine aminotransferase (alt)\>2.5×uln(upper limit of normal)，or total bilirubin (tbil)\>1.5×uln，or creatinine (cr)\>1.0×uln * absolute neutrophil count (anc) \< 1.5 × 10 \^ 9 / l；or platelet count (plt) \< 75 × 10 \^ 9 / l；or hemoglobin (hb) ≥ 90 g / l * previous or concurrent other active malignant tumors (except for basal cell carcinoma of the skin, or cervical cancer in situ that has undergone curative therapy) * distant metastases are present * any of the following conditions during the 12 months prior to entry: myocardial infarction, severe / unstable angina, coronary artery / peripheral artery bypass surgery, symptomatic congestive heart failure, or cerebrovascular accidents * positive human immunodeficiency virus (hiv) antibody * currently participating in other clinical trials * pregnant or lactating women or have fertility without taking contraception * suffering from other serious acute and chronic physical or mental problems, or abnormal laboratory tests, will increase the risk of participation or drug use, or interfere with the judgment of the findings, judged by the researchers as participate in the study

Keywords: progression-free survival gastrointestinal stromal tumors neoadjuvant
molecular assessment of oral mutans streptococcus isolated from different patients

Conditions: Dental Caries

Summary: 90 saliva samples will be isolated from patient who possess different ages and caries activity, attending outpatient clinic of october university of modern sciences and arts. then the determination of the best selective media for mutans streptococcus isolated from saliva and authenticate the ms via pcr technique.


Eligibility criteria:
inclusion criteria: * healthy participant exclusion criteria: * participant received antimicrobial therapy in previous month. * participant who taking xylitol chewing gum or undergo fluoride therapy.

Keywords: human saliva mutans streptococcus pcr caries activity
effect of dental scaling on helicobacter pylori eradication and reinfection

Conditions: Helicobacter Pylori Infection

Summary: patients who had received h.pylori eradication treatment will be categorised as eradication and reinfection status and whether dental scaling has any influence on these results.

patients over 18 years with no comorbidities especially liver, cardiac and haemorrhagic diathesis and giving informed consent will be categorised according to their status of dental scaling, eradication and reinfection rates of h.pylori. statistical examination will include the multiple regression and chi-square. the result will emphasize the influence of dental scaling on eradication (presence of hp cure 1-6 months after treatment) and reinfection ( reappearance of hp 12 months later than the treatment).

Eligibility criteria:
inclusion criteria: * patients over 18 with h.pylori positivity and received anti-hp treatment giving informed consent to analyse of their data on this subject. exclusion criteria: * comorbidities with cardiac, liver and medical contraindication to perform dental scaling.

Keywords: helicobacter pylori dental scaling eradication reinfection helicobacter status
diagnostic modalities for severe odontogenic infections using rapid, target enriched multiplex pcr (tem- pcr) by diatherix

Conditions: Odontogenic Deep Space Neck Infection

Summary: the purpose of the study is to evaluate the sensitivity and specificity of the target enriched multiplex (tem) polymerase chain reaction (pcr) platform for the rapid molecular diagnosis and treatment of odontogenic deep space neck infections.


Eligibility criteria:
inclusion criteria: * patients in whom there is clinical and radiographic evidence of an odontogenic deep space neck infection. exclusion criteria: * patients with gross communication between the abscess and the oral cavity will be excluded.